To explore the mechanism of Huangkui Capsules in the treatment of diabetic nephropathy based on network pharmacology and molecular docking.Methods:The chemical components of Huangkui Capsules were collected from ChemSrc,Chinese medicine and chemical component database,PubChem,and available literature.The active ingredients of Huangkui Capsules were screened from Swiss ADME and the target genes of the active ingredients in Huangkui Capsules were predicted by Swiss Target Prediction.The genes associated with diabetic nephropathy were obtained from GeneCards and Online Mendelian Inheritance in Man(OMIM).Venny2.1.0 was used to identify the key targets shared by Huangkui Capsules and diabetic nephropathy.R3.6.2 was used to perform gene ontology(GO) annotation and Kyoto Encyclopedia of Genes and Genome(KEGG) pathway enrichment for the key targets.Cytoscape 3.7.2 was employed to establish an “active ingredient-target-pathway” network for Huangkui Capsules in the prevention and treatment of diabetic nephropathy.Finally,AutoDock was used for molecular docking between active ingredients and key targets and calculating the lowest binding energy.Results:The major active ingredients of Huangkui Capsules in the treatment of diabetic nephropathy were 4',5,7,8-tetramethoxyflavone,quercetin,gallic acid,and protocatechuic acid,and the key targets were PIK3R1,PIK3CA,AKT1,SRC,and ESR1.The lowest binding energy between the active ingredients and the key targets was close to -5 kcal/mol.Huangkui Capsules may treat diabetic nephropathy via endocrine resistance,epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor resistance,hypoxia-inducible factor-1(HIF-1) signaling pathway,and estrogen signaling pathway.Conclusion:Huangkui Capsules can treat diabetic nephropathy through multiple ingredients,targets,and signaling pathways,which provides a theoretical basis for further research on Huangkui Capsules.